The National Institute on Drug Abuse (NIDA) offers this grant to support research on fentanyl and its analogs, addressing new challenges in treating addiction and overdose. This UG3/UH3 Phased Innovation Award, a two-phase grant, aims to quickly generate high-impact information. Projects will focus on opioid and polydrug use disorders impacted by fentanils. Research types include preclinical, clinical, epidemiological, and post-mortem studies. The grant supports developing new or repurposed medications/devices, revising therapeutic standards, and toxicological assessments, all with the goal of advancing treatments towards FDA approval for fentanyl-related Substance Use Disorders or overdose.
Opportunity ID: 335271
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-DA-22-022 |
| Funding Opportunity Title: | Fentanyl and its Analogs: Effects and Consequences for Treatment of Addiction and Overdose (UG3/UH3 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.279 — Drug Abuse and Addiction Research Programs |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Aug 12, 2021 |
| Last Updated Date: | Aug 12, 2021 |
| Original Closing Date for Applications: | Nov 11, 2021 |
| Current Closing Date for Applications: | Nov 11, 2021 |
| Archive Date: | Dec 17, 2021 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | State governments Others (see text field entitled “Additional Information on Eligibility” for clarification) Special district governments Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education Independent school districts For profit organizations other than small businesses City or township governments Small businesses Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this Funding Opportunity Announcement is to support research to understand and respond to new challenges in the treatment of drug addiction and overdose, introduced by the now widespread presence of fentanyl and its analogs (fentanils) in illicit drug supplies. The UG3/UH3 Phased Innovation Awards Cooperative Agreement involves 2 phases. The UG3 is to support a project with specific milestones to be accomplished by the end of the 2-year period. The UH3 is to provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases. Applications may focus on the treatment of opioid and polydrug use disorders where fentanils are a major contributor to the problem. The research may include preclinical, clinical, epidemiological or post-mortem studies, but should have high impact and quickly yield the necessary information to understand and effectively respond to the impacts of fentanils in illicit drug supplies. Studies might also aim to develop new or repurposed medications or therapeutic devices or aim to revise therapeutic standards of care. Research dependent on development and implementation of toxicological assessment techniques required to identify and quantitate fentanils and their metabolites, and other opioids or abused substances in clinical and post mortem toxicological samples may also be appropriate if the aims are to understand the public health consequences and treatment of disorders associated with the knowing or unknowing consumption of fentanils. Research to develop new therapeutic medications, indications or devices should be designed to significantly advance the program towards FDA approval for the treatment of fentanil-related Substance Use Disorders or overdose. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-022.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster OERWebmaster03@od.nih.gov Email: OERWebmaster03@od.nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-F | Use for due dates on or before January 24, 2022 | PKG00268543 | Oct 11, 2021 | Jan 24, 2022 | View |
Package 1
Mandatory forms
335271 RR_SF424_2_0-2.0.pdf
335271 PHS398_CoverPageSupplement_5_0-5.0.pdf
335271 RR_OtherProjectInfo_1_4-1.4.pdf
335271 PerformanceSite_2_0-2.0.pdf
335271 RR_KeyPersonExpanded_2_0-2.0.pdf
335271 RR_Budget_1_4-1.4.pdf
335271 PHS398_ResearchPlan_4_0-4.0.pdf
335271 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
335271 RR_SubawardBudget30_1_4-1.4.pdf
335271 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
